Exicure Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Exicure şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

Geri Alım Getirisi

Toplam Hissedar Getirisi	0%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Analiz Makalesi • Aug 29

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure, Inc. ( NASDAQ:XCUR ) shareholders won't be pleased to see that the share price has had a very rough month...

Seeking Alpha • Sep 26

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Early-stage biotech Exicure (NASDAQ:XCUR) on Monday announced a host of strategic actions, including a workforce reduction of about 66% and a halt to its research and development activities and its pre-clinical studies. The company estimated that it will incur total expenses relating to the restructuring of about $0.5M, adding that it expects the strategic actions to extend its cash runway into Q2 2023. XCUR said it would explore divestiture options for its SCN9A clinical program developing candidates for neuropathic pain, as results from a recent animal study did not meet "desired target engagement levels." In Monday's statement, XCUR also said it had entered into a private placement in public equity (PIPE) financing with existing investor CBI USA for anticipated gross proceeds of about $5.4M. CBI USA would also hold a controlling stake in XCUR equivalent to about 50.4% of the total voting power upon satisfaction of certain deal closing conditions. XCUR stock earlier closed +10.4% at $1.70.

Seeking Alpha • Aug 15

Exicure Q2 GAAP loss per share narrows, revenue up

Exicure press release (NASDAQ:XCUR): Q2 GAAP EPS of -$1.66 (vs. -$4.86 Y/Y). Revenue of $2.5M (vs. $0.1M Y/Y). Shares -9.05% AH.

Seeking Alpha • Jul 20

Exicure regains compliance with Nasdaq's minimum bid price requirement

Nasdaq has informed Exicure (NASDAQ:XCUR) that the biotechnology company has regained compliance with the stock exchange's $1.00 per share minimum bid price requirement. XCUR is now in compliance with all applicable listing standards, and the company's shares will continue to be listed and traded on the Nasdaq Capital Market. The shares closed at $1.72 on July 20. Source: Press Release

Seeking Alpha • Jun 29

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Exicure (NASDAQ:XCUR) announces that following the implementation of a one-for-thirty reverse stock split, the company’s common stock will begin trading on a split-adjusted basis on Nasdaq effective open of Thursday, June 30, 2022. On December 30, 2021, Nasdaq notified the company that it no longer satisfied the minimum bid price requirement as the bid price for the stock had closed below $1.00 per share for the previous thirty consecutive business days. Stock dumps ~31%.

Analiz Makalesi • Aug 25

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: XCUR şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: XCUR şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Exicure Piyasaya Karşı Temettü Getirisi

XCUR temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (XCUR)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.1%
Sektör Ortalaması (Biotechs)	2.1%
Analist tahmini (XCUR) (3 yıla kadar)	n/a

Önemli Temettü: XCUR şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, XCUR şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: XCUR şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: XCUR herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/10 08:32
Gün Sonu Hisse Fiyatı	2026/09/10 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Exicure, Inc. 5 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
null null	BMO Capital Markets Equity Research
Keay Nakae	Chardan Capital Markets, LLC
Yatin Suneja	Guggenheim Securities, LLC

Exicure Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

High number of new and inexperienced directors

Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Announces Resignation of Director Sangjin Yeo from Board and Audit Committee, Effective March 27, 2026

Exicure, Inc. Announces Resignation of Andy Yoo as Chief Executive Officer, Effective February 9, 2026

Exicure, Inc. Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure, Inc. Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma At 2025 Ash Annual Meeting

New major risk - Share price stability

New major risk - Financial position

Exicure, Inc. Announces New Leadership Strengthen Scientific and Clinical Capabilitie

High number of new and inexperienced directors

Exicure, Inc., Annual General Meeting, Nov 06, 2025

Exicure, Inc. Announces Board Changes

Less than half of directors are independent

Exicure, Inc. Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Receives Nasdaq Delinquency Notice on Late Filing of Its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure Completes Patient Enrollment in Phase 2 Study of Gpc-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Announces Their Next Step in Planning for A New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. Announces Board Resignations

New major risk - Shareholder dilution

Exicure, Inc. Announces Board Changes

Exicure Request for Subsequent Extension to Nasdaq Hearings Panel Till December 17

New minor risk - Shareholder dilution

Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024

Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure Receives Positive Listing Determination from Nasdaq

Exicure Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

Exicure, Inc., Annual General Meeting, Jun 28, 2024

Exicure, Inc. Receives Nasdaq Notice of A Delisting Determination

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. announced delayed annual 10-K filing

New minor risk - Financial data availability

No independent directors

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure Receives Non-Compliance Notice From Nasdaq

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure, Inc. Announces Executive Changes

Less than half of directors are independent

Exicure Notifies Nasdaq Regarding Continued to be Not in Compliance with Rule 5605(c)(2)(A)

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CBI USA Inc Sends a Letter to Exicure Inc

Exicure, Inc. announced delayed 10-Q filing

No independent directors

Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

Exicure Receives Notice from Nasdaq Regarding No Longer in Compliance with Nasdaq's Independent Director and Audit Committee Requirements

Exicure, Inc. Announces Resignation of Jiyoung Hwang from the Board of Directors

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Exicure Q2 GAAP loss per share narrows, revenue up

Exicure regains compliance with Nasdaq's minimum bid price requirement

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

Price target decreased to US$6.75

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Consensus revenue estimates increase to US$12.9m

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020)

Consensus revenue estimates increase to US$22.1m

Price target decreased to US$9.00

Consensus revenue estimates fall to US$5.77m

Price target decreased to US$9.60

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020)

Co-Founder & Director Chad Mirkin has left the company

Consensus revenue estimates increase to US$8.91m

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.46 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi